G1 Therapeutics stock movements
G1 Therapeutics (GTHX), a clinical-stage company, has risen 242.59% YTD (year-to-date), mainly due to its three important oncology research programs achieving major milestones. It was led by its most advanced clinical program for investigational first-in-class, short-acting, intravenously-administered cyclin-dependent kinase 4/6 (or CDK 4/6) inhibitor trilaciclib in the first half of 2018.
The consensus recommendation for G1 Therapeutics over the next 12 months is a “buy.” Of the six analysts covering the company in September, two have recommended a “strong buy,” and four have recommended a “buy.”
Wall Street analysts have projected a 12-month consensus target price for G1 Therapeutics of $67, which would be a decline of 1.43% over its closing price on September 13.
The above chart highlights the key milestone events that could impact G1 Therapeutics stock in the future.
G1 Therapeutics is targeting the myelopreservation market, worth more than $7 billion, with trilaciclib, which is currently being evaluated in multiple Phase 2 trials. The drug is being tested as a backbone therapy in combination regimens in first-line, second-line, and third-line small cell lung cancer, as well as in metastatic triple-negative breast cancers. All these indications are hard to treat, and the company thus expects to benefit from significant unmet demand in those areas.
It’s also targeting the oral CDK4/6 market, worth more than $20 billion, with investigational CDK4/6 inhibitor lerociclib. G1 It’s also targeting the selective estrogen receptor degrader (or SERD) market in the ER+ (estrogen-receptor-positive) breast cancer segment, which is worth more than $1 billion.
As of June 30, G1 Therapeutics had $188.2 million in cash on its balance sheet.
In the next part, we’ll look at the growth trends for Sarepta Therapeutics.